×
Please click
here
if you are not redirected within a few seconds.
All
News
Maps
Images
Videos
Shopping
Books
Search tools
Recent
Recent
Past hour
Past 24 hours
Past week
Past month
Past year
Archives
Sorted by relevance
Sorted by relevance
Sorted by date
CStone's sugemalimab recommended for metastatic NSCLC
Pharmaceutical Technology
EMA's CHMP has recommended the approval of CStone's sugemalimab for the first-line treatment of metastatic non-small cell lung cancer.
4 days ago
Rigel takes on US marketing of Blueprint's Gavreto
BioWorld MedTech
Blueprint Medicines Corp. found a new U.S. commercialization home for Gavreto (pralsetinib) through an agreement with Rigel Pharmaceuticals...
3 months ago
Natural Killer T Cell Lymphoma Market to Witness Upsurge in Growth During the Forecast Period | Janssen, Merck ...
openPR.com
Press release - ABNewswire - Natural Killer T Cell Lymphoma Market to Witness Upsurge in Growth During the Forecast Period | Janssen, Merck,...
2 weeks ago
M Stanley Stops Covering FORTUNE REIT, CHAMPION REIT, CSTONE PHARMA, CANBRIDGE, BRII
AASTOCKS.com
Morgan Stanley released a research report, announcing that it stops covering FORTUNE REIT (00778.HK), CHAMPION REIT (02778.HK), CSTONE...
2 weeks ago
Jiang loses chairman title as CStone seeks rebound from investment misstep
BioCentury
Investors appeared satisfied with the measures CStone is taking to address an investment that breached the company's own policies,...
24 months ago
Blueprint Medicines and CStone Pharmaceuticals Announce Exclusive Collaboration and License Agreement to ...
PR Newswire
PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ:BPMC), a leader in discovering and developing targeted kinase medicines for patients...
72 months ago
Ligand's Partner CStone Pharmaceuticals Receives Approval in China for Sugemalimab (Cejemly®) for the First-Line ...
Business Wire
EMERYVILLE, Calif.--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced that its partner CStone...
29 months ago
A first-in-human phase 1 study of nofazinlimab, an anti-PD-1 antibody, in advanced solid tumors and in combination ...
Nature
We assessed nofazinlimab, an anti-PD-1 antibody, in solid tumors and combined with regorafenib in metastatic colorectal cancer (mCRC).
8 months ago
Pfizer funnels $200M into CStone, licenses late-stage cancer med in China
Fierce Biotech
CStone Pharmaceuticals has seen a $200 million investment from U.S. Big Pharma Pfizer and nabbed a China license for its PD-L1 asset...
44 months ago
CStone, Pfizer Enter Antibody Alliance
Contract Pharma
To support CStone's development of sugemalimab, a potential best-in-class PD-L1 antibody being developed for high-incidence cancer...
44 months ago